BioSpace News Archive

Business

EyeGate Completes Enrollment in Phase IIb Clinical Trial of EGP-437 for Cataract Surgery

Topline data is expected to be released in the first quarter of 2018.

November 8, 2017
·
4 min read
Policy

Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury

CEVA101 is being developed in partnership with The University of Texas Health Science Center at Houston.

November 8, 2017
·
7 min read
Business

Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017

Investor conference call scheduled for 10 am ET today.

November 8, 2017
·
8 min read
Business

G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights

Operating expenses were $15.9 million for the third quarter of 2017, compared to $6.6 million for the third quarter of 2016.

November 8, 2017
·
7 min read
Business

G1 Therapeutics Makes Key Executive Appointments

The company appointed Barclay (Buck) Phillips as CFO and Sr. VP, Corporate Development, and Chandra Lovejoy as VP, Global Regulatory Affairs.

November 8, 2017
·
5 min read
Business

Axsome Therapeutics Reports Third Quarter 2017 Financial Results

As of September 30, 2017, Axsome had $31.7 million of cash compared to $36.6 million of cash as of December 31, 2016.

November 8, 2017
·
10 min read
Business

Neos Therapeutics Reports Third Quarter 2017 Financial Results

Total product revenues were $6.7 million for the three months ended September 30, 2017, compared to $1.6 million for the same period in 2016.

November 8, 2017
·
11 min read
Business

Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018

Paratek reported a net loss of $21.3 million, or ($0.77) per share, for the quarter ended September 30, 2017 compared to a net loss of $23.6 million, or ($1.04) per share, for the same period in 2016.

November 8, 2017
·
8 min read
Drug Development

Nightstar Expands Pipeline With Novel Gene Therapy for the Treatment of Stargardt Disease

Stargardt disease is the most common form of inherited juvenile macular dystrophy with a prevalence of one in 10,000.

November 8, 2017
·
5 min read
Arocell AB: Abstract Published Presenting Arocell TK 210 ELISA From the PROMIX Study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

The investigators quantified cell loss using the AroCell TK 210 ELISA kit to measure serum TK1 in serial samples from 145 breast cancer patients undergoing chemotherapy before surgery.

November 8, 2017
·
2 min read